Raloxifene dose for gynaecomastia is an important consideration for clinicians managing this common condition of benign male breast enlargement. Raloxifene, a selective oestrogen receptor modulator (SERM) licensed in the UK for osteoporosis, is used off-label at 60 mg once daily to reduce glandular breast tissue by blocking oestrogen receptors. Whilst small studies report encouraging results, the evidence base remains limited, and any prescription requires specialist oversight. This article outlines the clinical rationale, supporting evidence, safety profile, and NHS referral pathways relevant to raloxifene use in gynaecomastia.

What Is Raloxifene and How Does It Work in Gynaecomastia?

Raloxifene works by competitively binding to oestrogen receptors in male breast tissue, reducing glandular proliferation. The off-label dose studied is 60 mg once daily, mirroring its licensed osteoporosis dose.

Raloxifene is a selective oestrogen receptor modulator (SERM) — a class of medicine that interacts with oestrogen receptors in a tissue-specific manner. Both raloxifene and tamoxifen are SERMs: they exert anti-oestrogenic effects in breast tissue whilst acting as oestrogen agonists in bone and, to varying degrees, in other tissues. Raloxifene is licensed in the UK by the Medicines and Healthcare products Regulatory Agency (MHRA) primarily for the prevention and treatment of osteoporosis in postmenopausal women. It has been used off-label in the management of gynaecomastia, the benign enlargement of male breast tissue, though UK utilisation data are limited.

Gynaecomastia occurs when there is an imbalance between oestrogen and androgen activity in male breast tissue, leading to proliferation of glandular tissue beneath the nipple. Raloxifene works by competitively binding to oestrogen receptors in breast tissue, blocking the stimulatory effects of oestrogen and thereby reducing glandular proliferation.

In the context of gynaecomastia, the typical off-label dose studied in clinical settings has been 60 mg once daily, which mirrors the licensed osteoporosis dose. It is important to emphasise that raloxifene is not licensed for gynaecomastia in the UK, meaning any prescription would be at the discretion of a specialist clinician, and patients should not self-medicate.

Treatment is generally considered most effective during the active, proliferative phase of gynaecomastia — most sources suggest the best response is seen within the first 6–12 months of onset. Beyond one to two years, fibrous tissue progressively replaces glandular tissue, making medical therapy less likely to be effective.

Importantly, in line with the UK Summary of Product Characteristics (SmPC) for raloxifene, the medicine should be discontinued at least three days before and during any period of prolonged immobilisation (for example, post-operative recovery or extended bed rest), owing to the increased risk of venous thromboembolism (VTE). It should be restarted only once the patient is fully mobile.

Key UK references: emc SmPC: Evista (raloxifene hydrochloride); BNF (Raloxifene); NICE CKS: Gynaecomastia.

Evidence and Clinical Studies Supporting Its Use

Small observational studies using raloxifene 60 mg once daily for 3–6 months report reductions in glandular tissue in some patients, but robust RCT evidence is lacking and findings should be interpreted cautiously.

The evidence base for raloxifene in gynaecomastia, whilst encouraging, remains limited. The available data consist predominantly of small observational series and retrospective reviews rather than large-scale, well-powered randomised controlled trials (RCTs). Patients and clinicians should interpret the findings cautiously in light of these methodological limitations.

Small studies — including retrospective reviews and prospective observational series in adolescent and adult males with persistent pubertal or idiopathic gynaecomastia — have examined raloxifene at 60 mg once daily over periods of 3 to 6 months. These studies have generally reported reductions in breast disc diameter or glandular tissue volume in a meaningful proportion of participants, with some reporting greater than 50% reduction in tissue size in selected patients. However, sample sizes are small, outcome measures vary between studies, and the risk of bias is considerable.

Key points from the available evidence:

• Dose used: 60 mg once daily in most studies

• Duration: Typically 3 to 6 months

• Efficacy: Reductions in glandular tissue reported in a proportion of patients, though response rates vary across studies

• Comparison with tamoxifen: Robust head-to-head RCT evidence comparing raloxifene with tamoxifen in gynaecomastia is lacking. Tamoxifen (typically 10–20 mg daily) has a more extensive evidence base for medical management of gynaecomastia and is more widely referenced in specialist practice. Raloxifene may be considered as an off-label alternative in selected cases, usually under specialist guidance

NICE does not currently issue specific guidance on the use of SERMs for gynaecomastia, and NICE CKS notes that evidence for pharmacological therapy remains limited. Clinical decisions are guided by specialist endocrinology or surgical opinion, and treatment should always be individualised.

Key UK references: NICE CKS: Gynaecomastia; peer-reviewed observational studies of SERM use in gynaecomastia (interpret in context of study design and population).

Possible Side Effects and Safety Considerations

Raloxifene carries a clinically significant risk of VTE and is contraindicated in patients with a history of DVT or pulmonary embolism; common side effects include hot flushes, leg cramps, and peripheral oedema.

As with any medicine, raloxifene carries a risk of side effects that must be carefully considered — particularly given its off-label use in males, a population not included in the original licensing studies. The safety profile is largely derived from trials in postmenopausal women, and some caution is warranted when extrapolating to male patients.

Common side effects reported in licensed use include:

• Hot flushes — a vasomotor symptom that may be particularly noticeable in male patients

• Leg cramps — often mild but can be uncomfortable

• Peripheral oedema — swelling of the lower limbs

• Influenza-like symptoms in some individuals

Contraindications — do not use raloxifene if:

• There is a current or past history of venous thromboembolism (VTE), including deep vein thrombosis (DVT), pulmonary embolism, or retinal vein thrombosis. This is a contraindication in the UK SmPC, not merely a caution.

Serious risks and important warnings:

• VTE risk: Raloxifene carries a recognised, class-related increased risk of DVT and pulmonary embolism. Patients with additional thrombotic risk factors (e.g., obesity, prolonged immobility, thrombophilia) require careful individual risk assessment before commencing treatment.

• Immobilisation: Raloxifene must be stopped at least 3 days before and during any period of prolonged immobilisation (e.g., surgery, extended bed rest). It should only be restarted once the patient is fully mobile.

• Stroke risk: Data from the RUTH trial in postmenopausal women with established coronary heart disease identified a signal for increased risk of fatal stroke. Whilst this population differs from males being treated for gynaecomastia, this labelled warning should be acknowledged and individual cardiovascular risk factors considered.

Hepatic and renal impairment: Raloxifene should be used with caution in hepatic impairment (it is contraindicated in significant hepatic dysfunction) and in severe renal impairment. Prescribers should refer to the UK SmPC for full guidance.

Key drug interactions:

• Bile acid sequestrants (e.g., colestyramine) markedly reduce the absorption of raloxifene and should not be co-administered.

• Warfarin and other vitamin K antagonists: Raloxifene may modestly reduce prothrombin time; INR should be monitored if co-prescribed.

• Systemic oestrogens: Concomitant use should be avoided.

Patients should be counselled to report any sudden leg pain, swelling, breathlessness, or chest pain immediately, as these may indicate a thromboembolic event requiring urgent medical attention.

Suspected side effects should be reported to the MHRA via the Yellow Card scheme at yellowcard.mhra.gov.uk. Regular monitoring by a prescribing clinician is strongly advised throughout the treatment course.

Key UK references: emc SmPC: Evista (raloxifene hydrochloride); BNF (Raloxifene); EMA EPAR for raloxifene (Evista/Optruma).

When to Seek Medical Advice and NHS Treatment Options

Patients with persistent, painful, or distressing gynaecomastia should see their GP for investigation and possible specialist referral; red-flag features such as a hard irregular lump or nipple discharge require urgent assessment under NICE NG12.

Gynaecomastia is a common condition that, in many cases, resolves spontaneously — particularly in adolescent males where it is often a normal part of pubertal development. However, persistent, painful, or psychologically distressing gynaecomastia warrants a formal medical assessment. Patients should consult their GP in the first instance, who can arrange appropriate investigations and, if necessary, refer to an endocrinologist or breast surgeon.

Investigations typically recommended include:

• Serum testosterone, luteinising hormone (LH), and follicle-stimulating hormone (FSH)

• Oestradiol and prolactin levels

• Liver and renal function tests

• Thyroid function tests

• Beta-human chorionic gonadotrophin (beta-hCG) and alpha-fetoprotein (AFP) — to exclude hCG-secreting tumours and germ cell tumours

• Testicular examination, with testicular ultrasound where clinically indicated, to exclude a testicular or other hCG-secreting tumour

• Mammography or breast ultrasound if malignancy is suspected

Within the NHS, management follows a stepwise approach. Addressing any underlying cause — such as medication-induced gynaecomastia (e.g., from spironolactone, anabolic steroids, or antipsychotics), hypogonadism, or liver disease — is the primary intervention. Where no reversible cause is identified and the condition persists, surgical referral (subcutaneous mastectomy) may be considered, particularly if medical therapy has been ineffective. Note that NHS funding for surgery may be subject to local Integrated Care Board (ICB) commissioning policies; patients should discuss this with their local service.

Medical therapy with SERMs such as raloxifene or tamoxifen is generally initiated by a specialist, not in primary care, and is most appropriate during the early, active phase of gynaecomastia. Patients should not attempt to obtain or self-administer raloxifene without medical supervision, as incorrect use carries risks and may delay appropriate diagnosis.

Red-flag symptoms — seek urgent medical advice if you notice:

• A hard, irregular, or rapidly growing breast lump

• Nipple discharge or nipple retraction

• Skin changes over the breast (e.g., tethering, peau d'orange appearance)

• Axillary lymphadenopathy (swollen lymph nodes in the armpit)

These features may warrant an urgent suspected cancer referral in line with NICE NG12 (Suspected Cancer: Recognition and Referral), which sets out criteria for urgent referral of breast symptoms, including in men. Age-specific considerations apply; clinicians should refer to NG12 for full criteria.

Also seek urgent medical advice if you experience:

• Sudden swelling, pain, or redness in a leg

• Unexplained breathlessness or chest pain

For further guidance, patients and clinicians can refer to NICE CKS: Gynaecomastia, NICE NG12, and the NHS website: Gynaecomastia (enlarged male breasts), which provide up-to-date, evidence-aligned recommendations for assessment and referral pathways.

Key UK references: NICE CKS: Gynaecomastia; NICE NG12: Suspected cancer — recognition and referral; NHS: Gynaecomastia (enlarged male breasts).

Frequently Asked Questions